Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain excitatory neurons; strongest in late spermatids | 0.75 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 172 | 0.85 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 15065
Sealed predictions
- RFX1 in dopamine neurons, braak-0.32 (p 0.407) → -0.43 (p 0.247)receipt 15071
Swarm cases
receipt 15071: RFX1 in dopamine neurons, braak
- power
- full sample -0.42 (p 0.082, n 18), 95% CI -0.74 to +0.06. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.44 (p 0.066, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.47 (p 0.050, n 18). not the mix.
- skeptic
- leave-one-out range -0.51 to -0.34, sign flips 0; without severely affected donors -0.42 (p 0.082, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RFX1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts